While our findings are broadly consistent with a recent nationwide analysis of GLP-1 RA use and cancer risk in individuals with obesity [26], our study provides additional insights by focusing on a clearly defined early exposure period within a diabetes-specific population. Here, GLP1R is linked to cancer.